C.M. Perou

Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women

Jonine D. Figueroa, Dong‐Gun Lee, L. Wilkens, Niclas Håkansson et autres

Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast …

us (code pays fourni par la source)

Inherited predisposition to breast cancer in the Carolina Breast Cancer Study

M.A. Troester, C.M. Perou, T. N. Walsh, H.S. Earp et autres

The Carolina Breast Cancer Study (CBCS) phases I–II was a case-control study of biological and social risk factors for invasive breast cancer that enrolled cases and controls between 1993 and 1999. Case selection was population-based and stratified by ancestry and age at …

us (code pays fourni par la source)

Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer

M.A. Troester, Akshar Patel, M.I. Love, C.M. Perou et autres

Continuous risk of recurrence scores (CRS) based on tumor gene expression are vital prognostic tools for breast cancer. Studies have shown that Black women (BW) have higher CRS than White women (WW). Although systemic injustices contribute substantially to breast cancer disparities, evidence …

us (code pays fourni par la source)

Combined Associations of a Polygenic Risk Score and Classical Risk Factors with Breast Cancer Risk

Nasim Mavaddat, Minouk J. Schoemaker, Hiltrud Brauch, Thomas Brüning et autres

We evaluated the joint associations between a new 313-variant PRS (PRS313) and questionnaire-based breast cancer risk factors for women of European ancestry, using 72 284 cases and 80 354 controls from the Breast Cancer Association Consortium. Interactions were evaluated using standard logistic …

us (code pays fourni par la source)

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

A.M. Thompson, N.U. Rashid, Xuefeng Chen, S.M. Bevill et autres

Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibodies, like trastuzumab or pertuzumab, and ATP active site inhibitors like …

us (code pays fourni par la source)

Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications

S. Garcia-Recio, A.F. Olshan, W.F. Anderson, Xiaodong Sun et autres

us, in (code pays fourni par la source)